Table 3.
Correlations between peripheral lymphocyte subsets and clinicopathological features in ovarian
| Variables | Histology | FIGO stage | Platinum Response | ||||||
|---|---|---|---|---|---|---|---|---|---|
| HGSC | CCC | P | Early (I + II) | Late (III + IV) | P | Sensitive | Resistant | P | |
| CD3+ T cells (%) | 66.88 ± 9.46 | 73.27 ± 8.07 | 0.053 | 66.56 ± 10.91 | 67.27 ± 9.21 | 0.763 | 66.99 ± 7.44 | 66.07 ± 15.14 | 0.835 |
| CD3+CD4+T cells (%) | 38.43 ± 9.22 | 42.18 ± 7.65 | 0.241 | 39.19 ± 8.64 | 38.47 ± 9.18 | 0.748 | 39.48 ± 7.84 | 36.67 ± 12.59 | 0.458 |
| CD3+CD8+ T cells (%) | 26.49 ± 8.90 | 28.82 ± 10.94 | 0.464 | 26.73 ± 11.27 | 26.87 ± 8.93 | 0.951 | 27.63 ± 8.61 | 29.39 ± 12.85 | 0.565 |
| CD8+CD28+ T cells (%) | 7.07 ± 2.80 | 8.51 ± 2.88 | 0.145 | 7.70 ± 2.52 | 7.23 ± 2.83 | 0.489 | 7.53 ± 2.90 | 6.67 ± 3.58 | 0.374 |
| NK cells (CD3−CD56+) (%) | 18.37 ± 8.95 | 14.30 ± 6.96 | 0.188 | 17.89 ± 10.08 | 18.15 ± 8.88 | 0.908 | 17.15 ± 7.34 | 21.64 ± 15.33 | 0.323 |
| Tregs (CD4+CD25+CD127−)(%) | 12.91 ± 3.22 | 13.79 ± 4.14 | 0.445 | 13.20 ± 3.07 | 13.02 ± 3.26 | 0.830 | 12.50 ± 2.63 | 12.47 ± 4.24 | 0.976 |
| B cells (CD19+) (%) | 12.40 ± 5.24 | 10.20 ± 2.15 | 0.024 | 14.99 ± 5.81 | 12.13 ± 5.05 | 0.028 | 13.61 ± 6.03 | 9.86 ± 4.07 | 0.014 |
| CD4/CD8 ratio | 1.67 ± 0.85 | 1.74 ± 0.91 | 0.818 | 2.40 ± 2.69 | 1.64 ± 0.82 | 0.253 | 1.88 ± 1.83 | 1.55 ± 1.00 | 0.386 |
Abbreviations: HGSC High-Grade Serous Carcinoma, CCC Clear Cell Carcinoma, FIGO The International Federation of Gynecology and Obstetrics